FDA approves USGI Medical’s pivotal study of the POSE2.0 procedure for primary obesityThe FDA has approved an USGI Medical’s Investigational Device Exemption application to conduct a pivotal study of its POSE2.0...
USGI Medical completes Pilot Study of the POSE2.0 incisionless weight loss procedureThe FDA has acknowledged the successful completion of a pilot study of USGI Medical’s incisionless, endoscopic gastroplasty procedure,...
SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%1 day ago